Open an account

Summit Therapeutics

SMMT · NASDAQ

$16.09+$0.52 (+3.34%)TodayMarket closed ·
Prev close $15.57

About SMMT

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company is headquartered in Miami, Florida and currently employs 265 full-time employees. The company went IPO on 2004-10-14. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. The company is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Employees
265
Headquarters
Miami, Florida
Listed
Oct 14, 2004
Sector
Health Care
Industry
Biotechnology
Website
smmttx.com

SMMT key statistics

Market cap
12.45B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
6.96M
Volume
5.27M
Open price
$15.50
High today
$16.18
Low today
$15.06
52 Week high
$29.23
52 Week low
$12.07

Summit Therapeutics (SMMT) at a glance

Summit Therapeutics (SMMT) last traded at $16.09, with a market cap of 12.45B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $15.06 and $16.18. The current price is 6.8% above the day's low and 0.6% below its high.

Volume so far is 5.27M shares, below the average of 6.96M shares a day.

Over the past year Summit Therapeutics has ranged from $12.07 to $29.23, and now sits 23% of the way up that range.

Summit Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.28 per share against an estimate of -$0.2849.

The average analyst price target is $30.52, 89.7% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

42%of 12 analyst ratings say Buy
  • Buy41.7%
  • Hold58.3%
  • Sell0.0%
Price target · 16 analystsAvg $30.52
Low
$12.02
Now
$16.09
High
$45.15

SMMT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 2.8% on average.

  1. Q3 FY24: reported -$0.08 per share against an estimate of -$0.068
  2. Q4 FY24: reported -$0.08 per share against an estimate of -$0.0831
  3. Q1 FY25: reported -$0.09 per share against an estimate of -$0.0928
  4. Q2 FY25: reported -$0.12 per share against an estimate of -$0.0964
  5. Q3 FY25: reported -$0.31 per share against an estimate of -$0.1345
  6. Q4 FY25: reported -$0.29 per share against an estimate of -$0.0656
  7. Q1 FY26: reported -$0.24 per share against an estimate of -$0.1801
  8. Q2 FY26: reported -$0.28 per share against an estimate of -$0.2849

SMMT news

  • Press releaseBusiness Wire

    Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Piero Cingari

    Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%

  • Surbhi Jain

    Amazon, Alphabet, Tesla Stock Rises: Robinhood Traders Sell Anyway

  • Press releaseBusiness Wire

    AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

  • Vandana Singh

    AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership

  • Press releaseBusiness Wire

    Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

  • Press releaseBusiness Wire

    Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

Similar companies

Companies in the same industry as Summit Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.